Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
55.92
+2.08 (3.86%)
Nov 22, 2024, 4:00 PM EST - Market closed
Keros Therapeutics Employees
Keros Therapeutics had 136 employees as of December 31, 2023. The number of employees increased by 31 or 29.52% compared to the previous year.
Employees
136
Change (1Y)
31
Growth (1Y)
29.52%
Revenue / Employee
$4,787
Profits / Employee
-$1,335,074
Market Cap
2.27B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 136 | 31 | 29.52% |
Dec 31, 2022 | 105 | 45 | 75.00% |
Dec 31, 2021 | 60 | 25 | 71.43% |
Dec 31, 2020 | 35 | 12 | 52.17% |
Dec 31, 2019 | 23 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Addus HomeCare | 34,846 |
Ardent Health Partners | 23,000 |
CONMED | 4,000 |
Premier | 2,900 |
Amphastar Pharmaceuticals | 1,761 |
Wave Life Sciences | 268 |
Mirum Pharmaceuticals | 264 |
CG Oncology | 61 |
KROS News
- 16 days ago - Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewsWire
- 16 days ago - Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 3 months ago - Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - GlobeNewsWire
- 3 months ago - Keros Therapeutics Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 5 months ago - Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth - Benzinga
- 5 months ago - Keros Therapeutics Announces Leadership Updates - GlobeNewsWire
- 5 months ago - Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association - GlobeNewsWire
- 5 months ago - Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers - Seeking Alpha